Total Brain (ASX:TTBO) Total Stockholders Equity: A$6.80 Mil (As of Dec. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Total Brain Total Stockholders Equity?

Total Brain ASX:TTBO Total Stockholders Equity is A$6.80 Mil as of Dec. 2022. The stock has 6 warning signs investors should review.

Total Brain's Total Stockholders Equity for the quarter that ended in Dec. 2022 was A$6.80 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Total Brain's Book Value per Share for the quarter that ended in Dec. 2022 was A$N/A. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Total Brain's Debt-to-Equity for the quarter that ended in Dec. 2022 was 0.00.


Total Brain  (ASX:TTBO) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Total Brain's Book Value per Share for the quarter that ended in Dec. 2022 is

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Total Brain's Debt-to-Equity for the quarter that ended in Dec. 2022 is

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Total Brain Total Stockholders Equity Related Terms


Total Brain Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Total Brain's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Total Brain Total Stockholders Equity Chart

Total Brain Annual Data
Trend Jun13 Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 21.78 20.22 26.39 17.98 10.25

Total Brain Semi-Annual Data
Jun13 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.94 17.98 21.86 10.25 6.80
What does a Total Stockholders Equity of A$6.80 Mil mean?
Total Brain (ASX:TTBO) has a Total Stockholders Equity of A$6.80 Mil as of Dec. 2022. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Total Brain and its competitors.
Is Total Brain's Total Stockholders Equity too high?
Total Brain's current Total Stockholders Equity is A$6.80 Mil.
How does Total Brain's Total Stockholders Equity compare to PEARQ and BBLNF?
Total Brain's Total Stockholders Equity of A$6.80 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Healthcare Providers & Services company?
A good Total Stockholders Equity depends on the Healthcare Providers & Services industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Total Brain and its competitors. Total Brain's current Total Stockholders Equity is A$6.80 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Total Brain stock overvalued right now?
Total Brain (ASX:TTBO) has a current Total Stockholders Equity of A$6.80 Mil. The current Total Stockholders Equity is A$6.80 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Total Brain (ASX:TTBO), the current Total Stockholders Equity is A$6.80 Mil as of Dec. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Total Brain Business Description

Address 15 Belvoir Street, Surry Hills, NSW, AUS, 2010
Total Brain Ltd offers brain performance management platform. The company has build and validate digital tools to access, monitor, screen, and train the brain at the capacity makers level. It operates through one segment namely, development and commercialisation of brain health products.